Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1050
Gene Symbol: CEBPA
CEBPA
1.000 GeneticVariation disease BEFREE The value of allogeneic hematopoietic cell transplantation (alloHCT) as postremission treatment is not well defined for patients with intermediate-risk acute myeloid leukemia (AML) without FLT3-ITD, biallelic CEBPA-, or NPM1 mutations (here referred to as NPM1mut-neg/CEBPAdm-neg/FLT3-ITDneg AML) in first complete remission (CR1). 28945881 2018
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE BCRP mRNA and FLT3-ITD are independent poor risk factors in adult patients with acute myeloid leukemia and intermediate or normal karyotype. 28618074 2018
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation. 29423758 2018
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia. 29069942 2018
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 Biomarker disease BEFREE MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia. 29080039 2018
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation. 28616699 2018
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 Biomarker disease BEFREE FLT3 ITD AML disease progression is associated with cytogenetic evolution and acquired tyrosine kinase inhibitor (TKI) resistance suggesting a potential role of genomic instability. 28278729 2018
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 Biomarker disease BEFREE Fms-like tyrosine kinase 3 (FLT3) with internal tandem duplications (ITD) is a major oncoprotein in acute myeloid leukemia (AML), and confers an unfavorable prognosis. 28460451 2018
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 Biomarker disease BEFREE The value of allogeneic hematopoietic cell transplantation (alloHCT) as postremission treatment is not well defined for patients with intermediate-risk acute myeloid leukemia (AML) without FLT3-ITD, biallelic CEBPA-, or NPM1 mutations (here referred to as NPM1mut-neg/CEBPAdm-neg/FLT3-ITDneg AML) in first complete remission (CR1). 28945881 2018
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells. 28450419 2018
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation. 28283965 2017
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 Biomarker disease CTD_human FLT3 inhibitors are being developed as targeted therapy for FLT3-ITD(+) acute myeloid leukemia; however, their use is complicated by rapid development of resistance, which illustrates the need for additional therapeutic targets. 27099147 2017
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE Internal tandem duplication (ITD) mutation in Fms-like tyrosine kinase 3 gene (FLT3/ITD) represents an unfavorable genetic change in acute myeloid leukemia (AML) and is associated with poor prognosis. 28194038 2017
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 Biomarker disease BEFREE The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia. 28000291 2017
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 Biomarker disease BEFREE Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD). 27060207 2017
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 Biomarker disease BEFREE Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. 27778197 2017
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. 28052408 2017
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE Sorafenib is a promising agent for treating pediatric refractory acute myeloid leukemia (AML) exhibiting FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD); however, its optimal use needs to be established. 27571118 2017
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 Biomarker disease BEFREE Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. 28645776 2017
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE Using targeted sequencing from single cells and colonies from patient samples, we demonstrate tremendous clonal diversity in the majority of acute myeloid leukemia (AML) patients with activating <i>FLT3</i> internal tandem duplication mutations at the time of acquired resistance to the FLT3 inhibitor quizartinib. 28490572 2017
Entrez Id: 1050
Gene Symbol: CEBPA
CEBPA
1.000 GeneticVariation disease BEFREE Familial CEBPA-mutated acute myeloid leukemia. 28637622 2017
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 Biomarker disease BEFREE Midostaurin is a small-molecule kinase inhibitor with activity against the receptor tyrosine kinase FLT3, and its approval will hopefully mark the beginning of an era of targeted agents for the treatment of molecularly defined subtypes of AML. 28546144 2017
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. 27872058 2017
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE The FMS-like tyrosine kinase-3 (FLT3) gene is the most commonly mutated gene in acute myeloid leukemia (AML), and patients carrying internal tandem duplication (ITD) mutations have a poor prognosis. 27748370 2017
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. 28644114 2017